RxDoctor Payments Data

Carlos Lastra

Neurology with Special Qualifications in Child Neurology · New Brunswick, NJNPI 1144249137

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by UCB SA at 30.8% of the total. Reporting peaked in 2019 at $1,912 and has fallen 81.8% since, to $347 in 2025. Among neurology with special qualifications in child neurology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,749in general payments, 2019–2025

Across 51 payments — averaging $93.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$1K
  • H. Lundbeck A S$1K
  • Jazz Pharmaceuticals Inc.$600
  • Neurelis, Inc.$340
  • Greenwich Biosciences, Inc.$217
  • UCB, Inc.$140
  • plus $664 from 12 others
$497,655in research payments, 2019–2025

Across 177 payments — averaging $2811.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$110K
  • Aquestive Therapeutics, Inc.$82K
  • UCB SA$82K
  • Jazz Pharmaceuticals Inc.$75K
  • SK Life Science, Inc.$53K
  • Takeda Pharmaceuticals U.S.A., Inc.$46K
  • plus $49K from 3 others

What the payments were for

  • Travel & lodging$2,51253%
  • Food & beverage$2,23647%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,749 in reported general payments places this provider in the 90th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.

See all neurology with special qualifications in child neurology providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)29$94,358
ValtocoDiazepam31$31,781
FycompaPerampanel19$28,770
Clobazam56$11,206
Lamotrigine OdtLamotrigine11$3,423
Zonisamide23$996
Levetiracetam33$836
Lacosamide28$824
Divalproex Sodium ErDivalproex Sodium20$443
Divalproex Sodium19$365
Quetiapine Fumarate15$298
Aripiprazole15$245
Clonazepam14$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurelis, Inc.Valtoco$340$31,78131 claims
Eisai Inc.Fycompa$41$28,77019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.

Other neurology with special qualifications in child neurology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →